ATC Φάρμακα Δραστικές ICPC2 ICD10 Ιατρική στην Πράξη Νοσήματα Λοιμώξεις Εμβόλια Πρωτόκολλα
  • Tetrabenazine
  • indication:For the symptomatical treatment of hyperkinetic movement disorder.
  • pharmacologypharmacology:
  • mechanism: Tetrabenazine works mainly as a VMAT-inhibitor and as such promotes the early metabolic degradation of the neurotransmitter dopamine.
  • toxicity:
  • absorprion:
  • halflife:
  • roouteelimination: After oral administration, tetrabenazine is extensively hepatically metabolized, and the metabolites are primarily renally eliminated. In a mass balance study in 6 healthy volunteers, approximately 75% of the dose was excreted in the urine and fecal recovery accounted for approximately 7-16% of the dose. Urinary excretion of α-HTBZ or β-HTBZ (the major metabolites)accounted for less than 10% of the administered dose.
  • volumedistribution:
  • clearance: